Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)

Celia Moreno; Eduardo Ramos-Elbal; Pablo Velasco; Yurena Aguilar; Berta Gonzáález Martínez; Carolina Fuentes; Águeda Molinos; Pilar Guerra-García; Pilar Palomo; Jaime Verdu; Rosa María Adán Pedroso; José Manuel Vagace; Mónica López-Duarte; Alexandra Regueiro; María Tasso; José Luis Dapena; José Antonio Salinas; Samuel Navarro; Francisco Bautista; Álvaro Lassaletta; Francisco Lendínez; Susana Rives; Antonia Pascual; Antonia Rodríguez; José María Pérez-Hurtado; José María Fernández; Antonio Pérez-Martínez; Marta González-Vicent; Cristina Díaz de Heredia; José Luis Fuster

doi:10.3389/fped.2023.1140637

Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)

Celia Moreno, Eduardo Ramos-Elbal, Pablo Velasco, Yurena Aguilar, Berta Gonzáález Martínez, Carolina Fuentes, Águeda Molinos, Pilar Guerra-García, Pilar Palomo, Jaime Verdu, Rosa María Adán Pedroso, José Manuel Vagace, Mónica López-Duarte, Alexandra Regueiro, María Tasso, José Luis Dapena, José Antonio Salinas, Samuel Navarro, Francisco Bautista, Álvaro LassalettaFrancisco Lendínez, Susana Rives, Antonia Pascual, Antonia Rodríguez, José María Pérez-Hurtado, José María Fernández, Antonio Pérez-Martínez, Marta González-Vicent, Cristina Díaz de Heredia, José Luis Fuster

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

Samenvatting

INTRODUCTION: Studies addressing the role of haploidentical as alternative to HLA-matched donors for stem cell transplantation (SCT) often include patients with diverse hematological malignancies in different remission statuses.

METHODS: We compared outcomes of children with acute lymphoblastic leukemia (ALL) undergoing SCT in second complete remission (CR2) from haploidentical (n = 25) versus HLA-matched donor (n = 51).

RESULTS: Patients were equally distributed across both groups according to age, immunophenotype, time to and site of relapse, relapse risk-group allocation, and minimal residual disease (MRD) before SCT. Incidence of graft failure, acute graft versus host disease (GVHD), and other early complications did not differ between both groups. We found no differences in overall survival (58.7% versus 59.5%; p = .8), leukemia free survival (LFS) (48% versus 36.4%; p = .5), event free survival (40% versus 34.4%; p = .69), cumulative incidence (CI) of subsequent relapse (28% versus 40.9%; p = .69), treatment related mortality (24% versus 23.6%; p = .83), CI of cGVHD (4.5% versus 18.7%; p = .2), and chronic GVHD-free and leukemia-free survival (44% versus 26.3%; p = .3) after haploidentical donor SCT. Chronic GVHD (HR = 0.09; p=.02) had protective impact, and MRD ≥ 0.01% before SCT (HR = 2.59; p=.01) had unfavorable impact on LFS.

DISCUSSION: These results support the role of haploidentical donor SCT in children with ALL in CR2.

Originele taal-2	Engels
Pagina's (van-tot)	1140637
Tijdschrift	Frontiers in pediatrics
Volume	11
DOI's	https://doi.org/10.3389/fped.2023.1140637
Status	Gepubliceerd - 20 mrt. 2023
Extern gepubliceerd	Ja

Toegang tot document

10.3389/fped.2023.1140637

Vingerafdruk

Duik in de onderzoeksthema's van 'Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)'. Samen vormen ze een unieke vingerafdruk.

Citeer dit

Moreno, C., Ramos-Elbal, E., Velasco, P., Aguilar, Y., Gonzáález Martínez, B., Fuentes, C., Molinos, Á., Guerra-García, P., Palomo, P., Verdu, J., Adán Pedroso, R. M., Vagace, J. M., López-Duarte, M., Regueiro, A., Tasso, M., Dapena, J. L., Salinas, J. A., Navarro, S., Bautista, F., ... Fuster, J. L. (2023). Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet). Frontiers in pediatrics, 11, 1140637. https://doi.org/10.3389/fped.2023.1140637

Moreno, Celia ; Ramos-Elbal, Eduardo ; Velasco, Pablo et al. / Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission : A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet). In: Frontiers in pediatrics. 2023 ; Vol. 11. blz. 1140637.

@article{d6b5aa6d96354947bf4867d224b2ae41,

title = "Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)",

abstract = "INTRODUCTION: Studies addressing the role of haploidentical as alternative to HLA-matched donors for stem cell transplantation (SCT) often include patients with diverse hematological malignancies in different remission statuses.METHODS: We compared outcomes of children with acute lymphoblastic leukemia (ALL) undergoing SCT in second complete remission (CR2) from haploidentical (n = 25) versus HLA-matched donor (n = 51).RESULTS: Patients were equally distributed across both groups according to age, immunophenotype, time to and site of relapse, relapse risk-group allocation, and minimal residual disease (MRD) before SCT. Incidence of graft failure, acute graft versus host disease (GVHD), and other early complications did not differ between both groups. We found no differences in overall survival (58.7% versus 59.5%; p = .8), leukemia free survival (LFS) (48% versus 36.4%; p = .5), event free survival (40% versus 34.4%; p = .69), cumulative incidence (CI) of subsequent relapse (28% versus 40.9%; p = .69), treatment related mortality (24% versus 23.6%; p = .83), CI of cGVHD (4.5% versus 18.7%; p = .2), and chronic GVHD-free and leukemia-free survival (44% versus 26.3%; p = .3) after haploidentical donor SCT. Chronic GVHD (HR = 0.09; p=.02) had protective impact, and MRD ≥ 0.01% before SCT (HR = 2.59; p=.01) had unfavorable impact on LFS.DISCUSSION: These results support the role of haploidentical donor SCT in children with ALL in CR2.",

author = "Celia Moreno and Eduardo Ramos-Elbal and Pablo Velasco and Yurena Aguilar and {Gonz{\'a}{\'a}lez Mart{\'i}nez}, Berta and Carolina Fuentes and {\'A}gueda Molinos and Pilar Guerra-Garc{\'i}a and Pilar Palomo and Jaime Verdu and {Ad{\'a}n Pedroso}, {Rosa Mar{\'i}a} and Vagace, {Jos{\'e} Manuel} and M{\'o}nica L{\'o}pez-Duarte and Alexandra Regueiro and Mar{\'i}a Tasso and Dapena, {Jos{\'e} Luis} and Salinas, {Jos{\'e} Antonio} and Samuel Navarro and Francisco Bautista and {\'A}lvaro Lassaletta and Francisco Lend{\'i}nez and Susana Rives and Antonia Pascual and Antonia Rodr{\'i}guez and P{\'e}rez-Hurtado, {Jos{\'e} Mar{\'i}a} and Fern{\'a}ndez, {Jos{\'e} Mar{\'i}a} and Antonio P{\'e}rez-Mart{\'i}nez and Marta Gonz{\'a}lez-Vicent and {D{\'i}az de Heredia}, Cristina and Fuster, {Jos{\'e} Luis}",

note = "{\textcopyright} 2023 Moreno, Ramos-Elbal, Velasco, Aguilar, Gonz{\'a}lez, Fuentes, Molinos, Guerra-Garc{\'i}a, Palomo, Verdu, Ad{\'a}n, Vagace, Duarte, Regueiro, Tasso, Dapena, Salinas, Navarro, Bautista, Lassaletta, Lend{\'i}nez, Rives, Pascual, Rodr{\'i}guez, P{\'e}rez-Hurtado, Fern{\'a}ndez, P{\'e}rez-Mart{\'i}nez, Gonz{\'a}lez-Vicent, de Heredia and Fuster.",

year = "2023",

month = mar,

day = "20",

doi = "10.3389/fped.2023.1140637",

language = "English",

volume = "11",

pages = "1140637",

journal = "Frontiers in pediatrics",

issn = "2296-2360",

publisher = "Frontiers Media S.A.",

}

Moreno, C, Ramos-Elbal, E, Velasco, P, Aguilar, Y, Gonzáález Martínez, B, Fuentes, C, Molinos, Á, Guerra-García, P, Palomo, P, Verdu, J, Adán Pedroso, RM, Vagace, JM, López-Duarte, M, Regueiro, A, Tasso, M, Dapena, JL, Salinas, JA, Navarro, S, Bautista, F, Lassaletta, Á, Lendínez, F, Rives, S, Pascual, A, Rodríguez, A, Pérez-Hurtado, JM, Fernández, JM, Pérez-Martínez, A, González-Vicent, M, Díaz de Heredia, C & Fuster, JL 2023, 'Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)', Frontiers in pediatrics, vol. 11, blz. 1140637. https://doi.org/10.3389/fped.2023.1140637

Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet). / Moreno, Celia; Ramos-Elbal, Eduardo; Velasco, Pablo et al.
In: Frontiers in pediatrics, Vol. 11, 20.03.2023, blz. 1140637.

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

TY - JOUR

T1 - Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission

T2 - A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)

AU - Moreno, Celia

AU - Ramos-Elbal, Eduardo

AU - Velasco, Pablo

AU - Aguilar, Yurena

AU - Gonzáález Martínez, Berta

AU - Fuentes, Carolina

AU - Molinos, Águeda

AU - Guerra-García, Pilar

AU - Palomo, Pilar

AU - Verdu, Jaime

AU - Adán Pedroso, Rosa María

AU - Vagace, José Manuel

AU - López-Duarte, Mónica

AU - Regueiro, Alexandra

AU - Tasso, María

AU - Dapena, José Luis

AU - Salinas, José Antonio

AU - Navarro, Samuel

AU - Bautista, Francisco

AU - Lassaletta, Álvaro

AU - Lendínez, Francisco

AU - Rives, Susana

AU - Pascual, Antonia

AU - Rodríguez, Antonia

AU - Pérez-Hurtado, José María

AU - Fernández, José María

AU - Pérez-Martínez, Antonio

AU - González-Vicent, Marta

AU - Díaz de Heredia, Cristina

AU - Fuster, José Luis

N1 - © 2023 Moreno, Ramos-Elbal, Velasco, Aguilar, González, Fuentes, Molinos, Guerra-García, Palomo, Verdu, Adán, Vagace, Duarte, Regueiro, Tasso, Dapena, Salinas, Navarro, Bautista, Lassaletta, Lendínez, Rives, Pascual, Rodríguez, Pérez-Hurtado, Fernández, Pérez-Martínez, González-Vicent, de Heredia and Fuster.

PY - 2023/3/20

Y1 - 2023/3/20

N2 - INTRODUCTION: Studies addressing the role of haploidentical as alternative to HLA-matched donors for stem cell transplantation (SCT) often include patients with diverse hematological malignancies in different remission statuses.METHODS: We compared outcomes of children with acute lymphoblastic leukemia (ALL) undergoing SCT in second complete remission (CR2) from haploidentical (n = 25) versus HLA-matched donor (n = 51).RESULTS: Patients were equally distributed across both groups according to age, immunophenotype, time to and site of relapse, relapse risk-group allocation, and minimal residual disease (MRD) before SCT. Incidence of graft failure, acute graft versus host disease (GVHD), and other early complications did not differ between both groups. We found no differences in overall survival (58.7% versus 59.5%; p = .8), leukemia free survival (LFS) (48% versus 36.4%; p = .5), event free survival (40% versus 34.4%; p = .69), cumulative incidence (CI) of subsequent relapse (28% versus 40.9%; p = .69), treatment related mortality (24% versus 23.6%; p = .83), CI of cGVHD (4.5% versus 18.7%; p = .2), and chronic GVHD-free and leukemia-free survival (44% versus 26.3%; p = .3) after haploidentical donor SCT. Chronic GVHD (HR = 0.09; p=.02) had protective impact, and MRD ≥ 0.01% before SCT (HR = 2.59; p=.01) had unfavorable impact on LFS.DISCUSSION: These results support the role of haploidentical donor SCT in children with ALL in CR2.

AB - INTRODUCTION: Studies addressing the role of haploidentical as alternative to HLA-matched donors for stem cell transplantation (SCT) often include patients with diverse hematological malignancies in different remission statuses.METHODS: We compared outcomes of children with acute lymphoblastic leukemia (ALL) undergoing SCT in second complete remission (CR2) from haploidentical (n = 25) versus HLA-matched donor (n = 51).RESULTS: Patients were equally distributed across both groups according to age, immunophenotype, time to and site of relapse, relapse risk-group allocation, and minimal residual disease (MRD) before SCT. Incidence of graft failure, acute graft versus host disease (GVHD), and other early complications did not differ between both groups. We found no differences in overall survival (58.7% versus 59.5%; p = .8), leukemia free survival (LFS) (48% versus 36.4%; p = .5), event free survival (40% versus 34.4%; p = .69), cumulative incidence (CI) of subsequent relapse (28% versus 40.9%; p = .69), treatment related mortality (24% versus 23.6%; p = .83), CI of cGVHD (4.5% versus 18.7%; p = .2), and chronic GVHD-free and leukemia-free survival (44% versus 26.3%; p = .3) after haploidentical donor SCT. Chronic GVHD (HR = 0.09; p=.02) had protective impact, and MRD ≥ 0.01% before SCT (HR = 2.59; p=.01) had unfavorable impact on LFS.DISCUSSION: These results support the role of haploidentical donor SCT in children with ALL in CR2.

U2 - 10.3389/fped.2023.1140637

DO - 10.3389/fped.2023.1140637

M3 - Article

C2 - 37020654

SN - 2296-2360

VL - 11

SP - 1140637

JO - Frontiers in pediatrics

JF - Frontiers in pediatrics

ER -

Moreno C, Ramos-Elbal E, Velasco P, Aguilar Y, Gonzáález Martínez B, Fuentes C et al. Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet). Frontiers in pediatrics. 2023 mrt. 20;11:1140637. doi: 10.3389/fped.2023.1140637